Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization of Adjuvant Systemic Therapy in Early Breast Cancer With pCR and MRD-Negative (MolecularPCR)
NCT07407920Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2025
- Primary completion
- Sep 2028
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, trastuzumab, pertuzumab in triple negative breast cancer (TNBC), HER2-positive breast cancer, sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2025; status: recruiting.
02
Drugs
03
Conditions
triple negative breast cancer (TNBC)HER2-positive breast cancer
Beyond the preview
Go deeper on NCT07407920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07407920.